BR0011160A - Produção de vacinas de vìrus sinciciais respiratórios quiméricos atenuados a partiir de sequências de nucleotìdeos clonados - Google Patents
Produção de vacinas de vìrus sinciciais respiratórios quiméricos atenuados a partiir de sequências de nucleotìdeos clonadosInfo
- Publication number
- BR0011160A BR0011160A BR0011160-0A BR0011160A BR0011160A BR 0011160 A BR0011160 A BR 0011160A BR 0011160 A BR0011160 A BR 0011160A BR 0011160 A BR0011160 A BR 0011160A
- Authority
- BR
- Brazil
- Prior art keywords
- rsv
- chimeric
- attenuated
- offspring
- nucleotide sequences
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18541—Use of virus, viral particle or viral elements as a vector
- C12N2760/18543—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18561—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
"PRODUçãO DE VACINAS DE VìRUS SINCICIAIS RESPIRATóRIOS QUIMéRICOS ATENUADOS A PARTIR DE SEQuêNCIAS DE NUCLEOTìDEOS CLONADOS". Vírus sincicial respiratório quimérico (RSV ) e composições de vacina do mesmo são produzidos introduzindo um ou mais genes ou segmentos de genes heterólogos a partir de um subgrupo ou descendência de RSV em um fundo de RSV recipiente de um subgrupo ou descendência diferente. O vírus RSV quimérico ou partícula subviral resultante é infeccioso e atenuado, preferivelmente pela introdução de mutações selecionadas especificando fenótipos atenuados em um genoma ou antigenoma quimérico para produzir, por exemplo, descendências de vacina sensível à temperatura (ts) e/ou adaptadas ao frio (ca). Alternativamente, RSV quimérico e composições de vacina do mesmo incorporam outras mutações especificando características estruturais e/ou fenotípicas desejadas em um RSV quimérico infeccioso. Tal RSV quimérico incorpora mutações desejadas especificadas pela inserção, eliminação, substituição ou rearranjo de uma ou mais seq³ências de nucleotídeo, gene(s), ou segmento(s) de gene selecionados em um clone de RSV quimérico. Isto provê um método para desenvolvimento de novas vacinas contra descendências diversas de RSV usando uma cadeia principal atenuada comum como um vetor para expressar antígenos protetores de descendências heterólogas. O sistema imunológico de um individuo é estimulado para induzir proteção contra infecção de RSV natural, preferivelmente de uma maneira multivalente para conseguir proteção contra múltiplas descendências e/ou subgrupos de RSV.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/291,894 US6689367B1 (en) | 1995-09-27 | 1999-04-13 | Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences |
PCT/US2000/008802 WO2000061611A2 (en) | 1999-04-13 | 2000-03-31 | Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0011160A true BR0011160A (pt) | 2002-10-08 |
Family
ID=23122324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0011160-0A BR0011160A (pt) | 1999-04-13 | 2000-03-31 | Produção de vacinas de vìrus sinciciais respiratórios quiméricos atenuados a partiir de sequências de nucleotìdeos clonados |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP1690940A1 (pt) |
JP (1) | JP2002541785A (pt) |
KR (1) | KR100746979B1 (pt) |
CN (1) | CN100491530C (pt) |
AU (1) | AU4065500A (pt) |
BR (1) | BR0011160A (pt) |
CA (1) | CA2369200A1 (pt) |
IL (1) | IL145796A0 (pt) |
MX (1) | MXPA01010320A (pt) |
WO (1) | WO2000061611A2 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7485440B2 (en) | 1995-09-27 | 2009-02-03 | The United States Of America As Represented By The Department Of Health And Human Services | Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2 |
EP0859831B1 (en) * | 1995-09-27 | 2010-03-03 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Production of infectious respiratory syncytial virus from cloned nucleotide sequences |
US6699476B1 (en) | 1996-07-15 | 2004-03-02 | Peter L. Collins | Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules |
EP2112220A3 (en) | 1996-07-15 | 2010-01-06 | The Government of the United States of America, as represented by The Department of Health and Human Services | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences |
US7951383B2 (en) | 1997-05-23 | 2011-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuated parainfluenza virus (PIV) vaccines |
US7632508B2 (en) | 1997-05-23 | 2009-12-15 | The United States Of America | Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines |
US7201907B1 (en) | 1997-05-23 | 2007-04-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines |
US20030082209A1 (en) | 2000-07-05 | 2003-05-01 | Skiadopoulos Mario H. | Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines |
AU2006200619B2 (en) * | 1997-09-26 | 2007-12-13 | Medimmune, Llc | Recombinant RSV virus expression systems and vaccines |
AU5918100A (en) * | 1999-07-09 | 2001-01-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2 |
EP1287152B1 (en) | 1999-07-09 | 2008-12-31 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES | Human-bovine chimeric respiratory syncytial virus vaccines |
AU2003270824B2 (en) | 2002-09-18 | 2009-02-19 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens |
CA2517394A1 (en) | 2003-02-28 | 2005-02-17 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Recombinant human metapneumovirus and its use |
EP1633860A2 (en) | 2003-06-09 | 2006-03-15 | Wyeth | IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA |
US8597637B1 (en) * | 2010-05-18 | 2013-12-03 | Weidong Zhang | Breast cancer therapy using an engineered respiratory syncytial virus |
EP4190895A1 (en) | 2013-02-08 | 2023-06-07 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization |
WO2018057950A1 (en) | 2016-09-23 | 2018-03-29 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes |
CN107384958B (zh) * | 2017-07-14 | 2020-04-10 | 北京交通大学 | 基于反向遗传学构建的rsv反基因组质粒及其应用 |
CN113462656B (zh) * | 2021-03-24 | 2022-09-30 | 兰州生物制品研究所有限责任公司 | 一种人三型副流感病毒冷适应温度敏感株及其应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US708395A (en) | 1901-04-15 | 1902-09-02 | Oscar Peterson | Device for digging ditches. |
US2177396A (en) | 1936-04-18 | 1939-10-24 | Borden Co | Milk bottle |
US4614197A (en) | 1984-10-15 | 1986-09-30 | Deere & Company | Chaff spreading arrangement for a combine |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4763497A (en) | 1986-09-03 | 1988-08-16 | Clover Co., Ltd. | Lock device for double sliding doors |
US4800078A (en) | 1987-05-28 | 1989-01-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb |
IL105456A (en) | 1992-04-21 | 1996-12-05 | American Home Prod | Vaccines of attenuated respiratory syncytial virus |
US20030054505A1 (en) * | 1997-09-26 | 2003-03-20 | Hong Jin | Recombinant rsv expression systems and vaccines |
DE69510207T3 (de) | 1995-08-09 | 2007-02-15 | Schweiz. Serum- & Impfinstitut Bern | Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren |
JPH11512609A (ja) | 1995-09-27 | 1999-11-02 | アメリカ合衆国 | クローン化されたヌクレオチド配列からの感染性RSウイルス(respiratory syncytial virus)の生産 |
US6077514A (en) * | 1996-04-04 | 2000-06-20 | The Regents Of The University Of Michigan | Attenuated respiratory syncytial virus |
EP2112220A3 (en) | 1996-07-15 | 2010-01-06 | The Government of the United States of America, as represented by The Department of Health and Human Services | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences |
AU7797798A (en) | 1997-05-23 | 1998-12-11 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences |
US7208161B1 (en) | 1997-05-23 | 2007-04-24 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences |
CO5170419A1 (es) * | 1999-04-23 | 2002-06-27 | Smithkline Beecham Plc | Nuevo compuesto antidiabetico con base en sales del acido maleico |
-
2000
- 2000-03-31 WO PCT/US2000/008802 patent/WO2000061611A2/en not_active Application Discontinuation
- 2000-03-31 CA CA002369200A patent/CA2369200A1/en not_active Abandoned
- 2000-03-31 BR BR0011160-0A patent/BR0011160A/pt not_active Application Discontinuation
- 2000-03-31 MX MXPA01010320A patent/MXPA01010320A/es active IP Right Grant
- 2000-03-31 JP JP2000611553A patent/JP2002541785A/ja active Pending
- 2000-03-31 EP EP06075156A patent/EP1690940A1/en not_active Ceased
- 2000-03-31 AU AU40655/00A patent/AU4065500A/en not_active Abandoned
- 2000-03-31 CN CNB00806217XA patent/CN100491530C/zh not_active Expired - Lifetime
- 2000-03-31 EP EP00920058A patent/EP1169457A2/en not_active Ceased
- 2000-03-31 IL IL14579600A patent/IL145796A0/xx not_active IP Right Cessation
- 2000-03-31 KR KR1020017013099A patent/KR100746979B1/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1690940A1 (en) | 2006-08-16 |
EP1169457A2 (en) | 2002-01-09 |
KR100746979B1 (ko) | 2007-08-07 |
IL145796A0 (en) | 2002-07-25 |
WO2000061611A9 (en) | 2002-03-28 |
AU4065500A (en) | 2000-11-14 |
KR20020013526A (ko) | 2002-02-20 |
MXPA01010320A (es) | 2003-09-15 |
WO2000061611A2 (en) | 2000-10-19 |
CA2369200A1 (en) | 2000-10-19 |
JP2002541785A (ja) | 2002-12-10 |
CN100491530C (zh) | 2009-05-27 |
CN1364195A (zh) | 2002-08-14 |
WO2000061611A3 (en) | 2001-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0011160A (pt) | Produção de vacinas de vìrus sinciciais respiratórios quiméricos atenuados a partiir de sequências de nucleotìdeos clonados | |
Rauch et al. | New vaccine technologies to combat outbreak situations | |
BRPI9710363A (pt) | partícula de vírus sincicial respirátorio recombinante (rsv) infeccioso atenuado, vacina para induzir proteção contra o vírus sincicial respiratório recombinante (rsv), vetor de expressão, e, método de produção de um vírus sincicial respiratório recombinante (rsv) infeccioso. | |
Chen et al. | Advances in development and application of influenza vaccines | |
Wang et al. | Evidence of natural recombination within the S1 gens of infectious bronchitis virus | |
Subbarao et al. | Rescue of an influenza A virus wild-type PB2 gene and a mutant derivative bearing a site-specific temperature-sensitive and attenuating mutation | |
Murphy et al. | Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics | |
MX2022009429A (es) | Composiciones para la inmunizacion contra virus respiratorios. | |
Waring et al. | MicroRNA-based attenuation of influenza virus across susceptible hosts | |
ES2218276T3 (es) | Construstos de cromosomas artificiales que contienen secuencias de acidos nucleicos capaces de dirigir la formacion de un virus recombinante de arn. | |
DE60041280D1 (de) | Chimäre mensch-rinder respiratory syncytial virus vakzinen | |
HU229101B1 (en) | Dna transfection system for the generation of infectious influenza virus | |
MX2007007889A (es) | Rescate del virus de influenza. | |
US20210205436A1 (en) | Recombinant mopeia virus and vaccine platform | |
Stukova et al. | Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein | |
Rouxel et al. | Attenuated infectious hematopoietic necrosis virus with rearranged gene order as potential vaccine | |
JP2019500320A5 (pt) | ||
Wolf et al. | Salmonid alphavirus-based replicon vaccine against infectious salmon anemia (ISA): impact of immunization route and interactions of the replicon vector | |
Gutiérrez-Álvarez et al. | Middle East respiratory syndrome coronavirus vaccine based on a propagation-defective RNA replicon elicited sterilizing immunity in mice | |
EP2454374B1 (en) | Oral vaccines produced and administered using edible micro-organism | |
TW201333196A (zh) | 新穎減毒小兒麻痺病毒:pv-1單-cre-x | |
CN110904152A (zh) | 表达非洲猪瘟病毒p54蛋白的重组猪繁殖与呼吸综合征病毒的构建方法及其应用 | |
TW201910510A (zh) | 適用於黏膜傳遞之冷適應且去除毒力因子之減毒活疫苗 | |
BR0112276A (pt) | Vìrus sincicial respiratório recombinante infeccioso isolado, método para estimular o sistema imune de um indivìduo para induzir proteção contra rsv, composição imunogênica e molécula de polinucleotìdeo isolado | |
Chary et al. | Protection by recombinant viral proteins against a respiratory challenge with virulent avian metapneumovirus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 37, 8O, 11, 24, 25, 10, DA LPI |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |